Researchers from the University of Colorado Anschutz Medical Campus have identified a potential new immune checkpoint receptor that could lead to treatments for diseases such as lung and bowel cancer and autoimmune conditions including IBD.
The Washington-based CDMO AGC Biologics has been tapped to manufacture the type 1 diabetes treatment Tzield from Provention Bio. AGC Biologics will produce Tzield at its Seattle protein biologics site. It was chosen after AGC […]
In a three-year span, canned oxygen has become almost as available as the real thing. Buoyed by COVID-19, a “Shark Tank” deal, and a scene on “The Simpsons,” increased demand has resulted in a burst […]
Focusing the optimization of immunological response and tissue integration with implant surfaces LONGMONT, Colo., Oct. 13, 2022 /PRNewswire/ — Implant Surfaces LLC and CMDC Labs have agreed to expand a joint development effort to pursue […]
Copyright © 2023 Biotech Networks
